Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.
Takeshita, M.; Fukuyama, H.; Kamada, K.; Matsumoto, T.; Makino-Okamura, C.; Uchikubo-Kamo, T.; Tomabechi, Y.; Hanada, K.; Moriyama, S.; Takahashi, Y.; Ishigaki, H.; Nakayama, M.; Nguyen, C. T.; Kitagawa, Y.; Itoh, Y.; Imai, M.; Maemura, T.; Furusawa, Y.; Ueki, H.; Iwatsuki-Horimoto, K.; Ito, M.; Yamayoshi, S.; Kawaoka, Y.; Shirouzu, M.; Ishii, M.; Saya, H.; Kondo, Y.; Kaneko, Y.; Suzuki, K.; Fukunaga, K.; Takeuchi, T.
Show abstract
The use of therapeutic neutralizing antibodies against SARS-CoV-2 infection has been highly effective. However, there remain few practical antibodies against viruses that are acquiring mutations. In this study, we created 494 monoclonal antibodies from COVID-19-convalescent patients, and identified antibodies that exhibited comparable neutralizing ability to clinically used antibodies in the neutralization assay using pseudovirus and authentic virus including variants of concerns. These antibodies have different profiles against various mutations, which were confirmed by cell-based assay and cryo-electron microscopy. To prevent antibody-dependent enhancement, N297A modification was introduced, and showed a reduction of lung viral RNAs by therapeutic administration in a hamster model. In addition, an antibody cocktail consisting of three antibodies was also administered therapeutically to a macaque model, which resulted in reduced viral titers of swabs and lungs and reduced lung tissue damage scores. These results showed that our antibodies have sufficient antiviral activity as therapeutic candidates.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 97%
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 96%
- Nasal delivery of single-domain antibodies improve symptoms of SARS-CoV-2 infection in an animal model 95%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern 96%
- Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins 96%
- Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans 95%
Similar papers in this journal
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 96%
- A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus 95%
- Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.